















































75. Milanese, M.; Riccio, A.M.; Gamalero, C.; De Giovanni, B.; Bricchetto, L.; Baroffio, M.; Crimi, E.; Brusasco, V.; Canonica, G.W. A model of allergen-driven human airway contraction: beta<sub>2</sub>- pathway dysfunction without cytokine involvement. *Ann. Allergy Asthma Immunol.* **2005**, *94*, 273–278.
76. Song, P.; Milanese, M.; Crimi, E.; Rehder, K.; Brusasco, V. Allergen challenge of passively sensitized human bronchi alters M<sub>2</sub>- and beta<sub>2</sub>-receptor function. *Am. J. Respir. Crit. Care Med.* **1997**, *155*, 1230–1234.
77. Song, P.; Crimi, E.; Milanese, M.; Duan, J.; Rehder, K.; Brusasco, V. Anti-inflammatory agents and allergen-induced beta<sub>2</sub>-receptor dysfunction in isolated human bronchi. *Am. J. Respir. Crit. Care Med.* **1998**, *158*, 1809–1814.
78. Rovati, G.E.; Baroffio, M.; Citro, S.; Bricchetto, L.; Ravasi, S.; Milanese, M.; Crimi, E.; Brusasco, V. Cysteinyl-leukotrienes in the regulation of beta<sub>2</sub>-adrenoceptor function: an *in vitro* model of asthma. *Respir. Res.* **2006**, *7*, 103–113.
79. Benovic, J.L.; Mayor, F., Jr.; Staniszewski, C.; Lefkowitz, R.J.; Caron, M.G. Purification and characterization of the beta-adrenergic receptor kinase. *J. Biol. Chem.* **1987**, *262*, 9026–9032.
80. Benovic, J.L.; Kühn, H.; Weyand, I.; Codina, J.; Caron, M.G.; Lefkowitz, R.J. Functional desensitization of the isolated beta-adrenergic receptor by the beta-adrenergic receptor kinase: potential role of an analog of the retinal protein arrestin (48-kDa protein). *Proc. Natl. Acad. Sci. USA* **1987**, *84*, 8879–8882.
81. Lohse, M.J.; Benovic, J.L.; Codina, J.; Caron, M.G.; Lefkowitz, R.J. Beta-Arrestin: A protein that regulates beta-adrenergic receptor function. *Science* **1990**, *248*, 1547–1550.
82. Rajagopal, S.; Kim, J.; Ahn, S.; Craig, S.; Lam, C.M.; Gerard, N.P.; Gerard, C.; Lefkowitz, R.J. Beta-arrestin- but not G protein-mediated signaling by the "decoy" receptor CXCR7. *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 628–632.
83. Nino, G.; Hu, A.; Grunstein, J.S.; Grunstein, M. Mechanism regulating proasthmatic effects of prolonged homologous β<sub>2</sub>-adrenergic receptor desensitization in airway smooth muscle. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **2009**, *297*, L746–L757.
84. Wang, W.C.; Mihlbachler, K.A.; Brunnett, A.C.; Liggett, S.B. Targeted transgenesis reveals discrete attenuator functions of GRK and PKA in airway beta<sub>2</sub>-adrenergic receptor physiologic signaling. *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 15007–15012.
85. Giembycz, M.A. An estimation of beta<sub>2</sub>-adrenoceptor reserve on human bronchial smooth muscle for some sympathomimetic bronchodilators. *Br. J. Pharmacol.* **2009**, *158*, 287–299.
86. Yu, S.S.; Lefkowitz, R.J.; Hausdorff, W.P. Beta-adrenergic receptor sequestration. A potential mechanism of receptor resensitization. *J. Biol. Chem.* **1993**, *268*, 337–341.
87. Hadcock, J.R.; Wang, H.Y.; Malbon, C.C. Agonist-induced destabilization of beta-adrenergic receptor mRNA. Attenuation of glucocorticoid-induced up-regulation of beta-adrenergic receptors. *J. Biol. Chem.* **1989**, *264*, 19928–19933.

88. Collins, S.; Bouvier, M.; Bolanowski, M.A.; Caron, M.G.; Lefkowitz, R.J. cAMP stimulates transcription of the beta<sub>2</sub>-adrenergic receptor gene in response to short-term agonist exposure. *Proc. Natl. Acad. Sci. USA* **1989**, *86*, 4853–4857.
89. Huang, L.Y.; Tholanikunnel, B.G.; Vakalopoulou, E.; Malbon, C.C. The M(r) 35,000 beta-adrenergic receptor mRNA-binding protein induced by agonists requires both an AUUUA pentamer and U-rich domains for RNA recognition. *J. Biol. Chem.* **1993**, *268*, 25769–25775.
90. Bouvier, M.; Collins, S.; O'Dowd, B.F.; Campbell, P.T.; de Blasi, A.; Kobilka, B.K.; MacGregor, C.; Irons, G.P.; Caron, M.G.; Lefkowitz, R.J. Two distinct pathways for cAMP-mediated down-regulation of the beta<sub>2</sub>-adrenergic receptor. Phosphorylation of the receptor and regulation of its mRNA level. *J. Biol. Chem.* **1989**, *264*, 16786–16792.
91. Valiquette, M.; Bonin, H.; Hnatowich, M.; Caron, M.G.; Lefkowitz, R.J.; Bouvier, M. Involvement of tyrosine residues located in the carboxyl tail of the human beta<sub>2</sub>-adrenergic receptor in agonist-induced down-regulation of the receptor. *Proc. Natl. Acad. Sci. USA* **1990**, *87*, 5089–5093.
92. Kraan, J.; Koëter, G.H.; vd Mark, T.W.; Sluiter, H.J.; de Vries, K. Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. *J. Allergy Clin. Immunol.* **1985**, *76*, 628–636.
93. Kerrebijn, K.F.; van Essen-Zandvliet, E.E.; Neijens, H.J. Effect of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma. *J. Allergy Clin. Immunol.* **1987**, *79*, 653–659.
94. van Schayck, C.P.; Graafsma, S.J.; Visch, M.B.; Dompeling, E.; van Weel, C.; van Herwaarden, C.L. Increased bronchial hyperresponsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamol. *J. Allergy Clin. Immunol.* **1990**, *86*, 793–800.
95. Cheung, D.; Timmers, M.C.; Zwinderman, A.H.; Bel, E.H.; Dijkman, J.H.; Sterk, P.J. Long-term effects of a long-acting beta<sub>2</sub>-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. *N. Engl. J. Med.* **1992**, *327*, 1198–1203.
96. McGraw, D.W.; Almoosa, K.F.; Paul, R.J.; Kobilka, B.K.; Liggett, S.B. Antithetic regulation by β-adrenergic receptors of G<sub>q</sub> receptor signaling *via* phospholipase C underlies the airway β-agonist paradox. *J. Clin. Invest.* **2003**, *112*, 619–626.
97. Barnes, P.J. Scientific rationale for using a single inhaler for asthma control. *Eur. Respir. J.* **2007**, *29*, 587–595.
98. Callaerts-Vegh, Z.; Evans, K.L.; Dudekula, N.; Cuba, D.; Knoll, B.J.; Callaerts, P.F.; Giles, H.; Shardonofsky, F.R.; Bond, R.A. Effects of acute and chronic administration of beta-adrenoceptor ligands on airway function in a murine model of asthma. *Proc. Natl. Acad. Sci. USA* **2004**, *101*, 4948–4953.
99. Nguyen, L.P.; Omoluabi, O.; Parra, S.; Frieske, J.M.; Clement, C.; Ammar-Aouchiche, Z.; Ho, S.B.; Ehre, C.; Kesimer, M.; Knoll, B.J.; *et al.* Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model *Am. J. Respir. Cell. Mol. Biol.* **2008**, *38*, 256–262.

100. Hanania, N.A.; Singh, S.; El-Wali, R.; Flashner, M.; Franklin, A.E.; Garner, W.J.; Dickey, B.F.; Parra, S.; Ruoss, S.; Shardonofsky, F.; *et al.* The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study. *Pulm. Pharmacol. Ther.* **2008**, *21*, 134–141.
101. Lipworth, B.J.; Williamson, P.A. Beta blockers for asthma: a double-edged sword. *Lancet* **2009**, *373*, 104–105.
102. Hanania, N.A.; Dickey, B.F.; Bond, R.A. Clinical implications of the intrinsic efficacy of beta-adrenoceptor drugs in asthma: full, partial and inverse agonism. *Curr. Opin. Pulm. Med.* **2010**, *16*, 1–5.
103. Davies, A.O.; Lefkowitz, R.J. *In vitro* desensitization of beta-adrenergic receptors in human neutrophils. Attenuation by corticosteroids. *J. Clin. Invest.* **1983**, *71*, 565–571.
104. Bricchetto, L.; Milanese, M.; Song, P.; Patrone, M.; Crimi, E.; Rehder, K.; Brusasco, V. Beclomethasone rapidly ablates allergen-induced beta<sub>2</sub>-adrenoceptor pathway dysfunction in human isolated bronchi. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **2003**, *284*, L133–L139.
105. Green, S.A.; Turki, J.; Hall, I.P.; Liggett, S.B. Implications of genetic variability of human beta<sub>2</sub>-adrenergic receptor structure. *Pulm. Pharmacol.* **1995**, *8*, 1–10.
106. Liggett, S.B. Genetics of beta<sub>2</sub>-adrenergic receptor variants in asthma. *Clin. Exp. Allergy* **1995**, *Suppl. 2*, 89–94.
107. Kazani, S.; Wechsler, M.E.; Israel, E. The role of pharmacogenomics in improving the management of asthma. *J. Allergy Clin. Immunol.* **2010**, *125*, 295–302.
108. Taylor, D.R.; Drazen, J.M.; Herbison, G.P.; Yandava, C.N.; Hancox, R.J.; Town, G.I. Asthma exacerbations during long term beta-agonist use: influence of beta<sub>2</sub>-adrenoceptor polymorphism. *Thorax* **2000**, *55*, 762–767.
109. Basu, K.; Palmer, C.N.; Tavendale, R.; Lipworth, B.J.; Mukhopadhyay, S. Beta<sub>2</sub>-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol. *J. Allergy Clin. Immunol.* **2009**, *124*, 1188–1194.
110. Wechsler, M.E.; Kunselman, S.J.; Chinchilli, V.M.; Bleecker, E.; Boushey, H.A.; Calhoun, W.J.; Ameredes, B.T.; Castro, M.; Craig, T.J.; Denlinger, L.; *et al.* Effect of beta<sub>2</sub>-adrenergic receptor polymorphism on response to long-acting beta<sub>2</sub>-agonist in asthma (LARGE trial): A genotype-stratified, randomised, placebo-controlled, crossover trial. *Lancet* **2009**, *374*, 1754–1764.
111. Wang, W.C.; Mihalbachler, K.A.; Bleecker, E.R.; Weiss, S.T.; Liggett, S.B. A polymorphism of G-protein coupled receptor kinase 5 alters agonist-promoted desensitization of beta<sub>2</sub>-adrenergic receptors. *Pharmacogenet. Genomics* **2008**, *18*, 729–732.
112. Hall, I.P.; Wheatley, A.; Wilding, P.; Liggett, S.B. Association of Glu 27 beta<sub>2</sub>-adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects. *Lancet* **1995**, *345*, 1213–1214.
113. Litonjua, A.A.; Lasky-Su, J.; Schneiter, K.; Tantisira, K.G.; Lazarus, R.; Klanderman, B.; Lima, J.J.; Irvin, C.G.; Peters, S.P.; Hanrahan, J.P.; *et al.* ARG1 is a novel bronchodilator response gene: screening and replication in four asthma cohorts. *Am. J. Respir. Crit. Care Med.* **2008**, *178*, 688–694.
114. Nelson, H.S. β-Adrenergic bronchodilators. *N. Engl. J. Med.* **1995**, *333*, 499–506.



115. Lipworth, B.J.; Struthers, A.D.; McDevitt, D.G. Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics. *Am. Rev. Respir. Dis.* **1989**, *140*, 586–592.
116. Drazen, J.M.; Israel, E.; Boushey, H.A.; Chinchilli, V.M.; Fahy, J.V.; Fish, J.E.; Lazarus, S.C.; Lemanske, R.F.; Martin, R.J.; Peters, S.P.; *et al.* Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. *N. Engl. J. Med.* **1996**, *335*, 841–847.
117. Israel, E.; Drazen, J.M.; Liggett, S.B.; Boushey, H.A.; Cherniack, R.M.; Chinchilli, V.M.; Cooper, D.M.; Fahy, J.V.; Fish, J.E.; Ford, J.G.; *et al.* The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. *Am. J. Respir. Crit. Care Med.* **2000**, *162*, 75–80.
118. Israel, E.; Chinchilli, V.M.; Ford, J.G.; Boushey, H.A.; Cherniack, R.; Craig, T.J.; Deykin, A.; Fagan, J.K.; Fahy, J.V.; Fish, J.; *et al.* Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. *Lancet* **2004**, *364*, 1505–1512.
119. Milanese, M.; Saporiti, R.; Bartolini, S.; Pellegrino, R.; Baroffio, M.; Brusasco, V.; Crimi, E. Bronchodilator effects of exercise hyperpnea and albuterol in mild-to-moderate asthma. *J. Appl. Physiol.* **2009**, *107*, 494–499.
120. Hendeles, L.; Colice, G.L.; Meyer, R.J. Withdrawal of albuterol inhalers containing chlorofluorocarbon propellants. *N. Engl. J. Med.* **2007**, *356*, 1344–1351.
121. Ramsdell, J.W.; Colice, G.L.; Ekholm, B.P.; Klinger, N.M. Cumulative dose response study comparing HFA-134a albuterol sulfate and conventional CFC albuterol in patients with asthma. *Ann. Allergy Asthma Immunol.* **1998**, *81*, 593–599.
122. Cates, C.J.; Crilly, J.A.; Rowe, B.H. Holding chambers (spacers) versus nebulizers for beta-agonist treatment of acute asthma. *Cochrane Database Syst. Rev.* **2006**, *2*, CD000052–CD000052.
123. Henderson, W.R., Jr.; Banerjee, E.R.; Chi, E.Y. Differential effects of (S)- and (R)-enantiomers of albuterol in a mouse asthma model. *J. Allergy Clin. Immunol.* **2005**, *116*, 332–340.
124. Berger, W.E.; Milgrom, H.; Skoner, D.P.; Tripp, K.; Parsey, M.V.; Baumgartner, R.A.; Xopenex Pediatric Asthma Group. Evaluation of levalbuterol metered dose inhaler in pediatric patients with asthma: a double-blind, randomized, placebo- and active-controlled trial. *Curr. Med. Res. Opin.* **2006**, *22*, 1217–1226.
125. O'Byrne, P.M.; Bisgaard, H.; Godard, P.P.; Pistolesi, M.; Palmqvist, M.; Zhu, Y.; Ekström, T.; Bateman ED. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. *Am. J. Respir. Crit. Care Med.* **2005**, *171*, 129–136.
126. Pearlman, D.S.; Chervinsky, P.; LaForce, C.; Seltzer, J.M.; Southern, D.L.; Kemp, J.P.; Dockhorn, R.J.; Grossman, J.; Liddle, R.F.; Yancey, S.W.; *et al.* A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. *N. Engl. J. Med.* **1992**, *327*, 1420–1425.
127. Nelson, J.A.; Strauss, L.; Skowronski, M.; Ciufo, R.; Novak, R.; McFadden, E.R., Jr. Effect of long-term salmeterol treatment on exercise-induced asthma. *N. Engl. J. Med.* **1998**, *339*, 141–146.

128. Weinberger, M.; Abu-Hasan, M. Life-threatening asthma during treatment with salmeterol. *N. Engl. J. Med.* **2006**, *355*, 852–853.
129. Smyth, E.T.; Pavord, I.D.; Wong, C.S.; Wisniewski, A.F.; Williams, J.; Tattersfield, A.E. Interaction and dose equivalence of salbutamol and salmeterol in patients with asthma. *Br. Med. J.* **1993**, *306*, 543–545.
130. Appleton, S.; Poole, P.; Smith, B.; Veale, A.; Bara A. Long-acting  $\beta_2$ -agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation. *Cochrane Database Syst. Rev.* **2002**, *3*, CD001104.
131. D'Urzo, A.D.; De Salvo, M.C.; Ramirez-Rivera, A.; Almeida, J.; Sichletidis, L.; Rapatz, G.; Kottakis, J.; FOR-INT-03 Study Group. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium: a 3-week, randomized, double-blind, within-patient, multicenter study. *Chest* **2001**, *119*, 1347–1356.
132. Barnes, P.J.; Stockley, R.A. COPD: current therapeutic interventions and future approaches. *Eur. Respir. J.* **2005**, *25*, 1084–1106.
133. Goldkorn, A.; Diotto, P.; Burgess, C.; Weatherall, M.; Holt, S.; Beasley, R.; Siebers, R. The pulmonary and extra-pulmonary effects of high-dose formoterol in COPD: a comparison with salbutamol. *Respirology* **2004**, *9*, 102–108.
134. Sovrani, M.P.; Whale, C.I.; Tattersfield, A.E. A benefit-risk assessment of inhaled long-acting  $\beta_2$ -agonists in the management of obstructive pulmonary disease. *Drug Safety* **2004**, *27*, 689–715.
135. Lazarus, S.C.; Boushey, H.A.; Fahy, J.V.; Chinchilli, V.M.; Lemanske, R.F., Jr.; Sorkness, C.A.; Kraft, M.; Fish, J.E.; Peters, S.P.; Craig, T.; *et al.* Long-acting beta<sub>2</sub>-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. *JAMA* **2001**, *285*, 2583–2593.
136. Gibson, P.G.; Powell, H.; Ducharme, F.M. Differential effects of maintenance long-acting beta-agonist and inhaled corticosteroid on asthma control and asthma exacerbations. *J. Allergy Clin. Immunol.* **2007**, *119*, 344–350.
137. Woolcock, A.; Lundback, B.; Ringdal, N.; Jacques, L.A. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. *Am. J. Respir. Crit. Care Med.* **1996**, *153*, 1481–1488.
138. Pauwels, R.A.; Löfdahl, C.G.; Postma, D.S.; Tattersfield, A.E.; O'Byrne, P.; Barnes, P.J.; Ullman, A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. *N. Engl. J. Med.* **1997**, *337*, 1405–1411. [Erratum, *N. Engl. J. Med.* **1998**, *338*, 139.]
139. Giembycz, M.A.; Kaur, M.; Leigh, R.; Newton, R. A Holy Grail of asthma management: toward understanding how long-acting  $\beta_2$ -adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids. *Br. J. Pharmacol.* **2008**, *153*, 1090–1104.
140. Papi, A.; Canonica, G.W.; Maestrelli, P.; Paggiaro, P.L.; Olivieri, D.; Pozzi, E.; Crimi, N.; Vignola, A.M.; Morelli, P.; Nicolini, G.; *et al.* Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. *N. Engl. J. Med.* **2007**, *356*, 2040–2052.

141. Barger, G.; Dale, H.H. Chemical structure and sympathomimetic action of amines. *J. Physiol. (Lond.)*, **1910**, *41*, 19–59.
142. Benson, R.L.; Perlman, F. Clinical effects of epinephrine by inhalation. *J. Allergy* **1948**, *19*, 129–140.
143. Davies, D.S. Metabolism of isoprenaline and other bronchodilator drugs in man and dog. *Bull. Physiopathol. Respir.* **1972**, *8*, 679–682.
144. Speizer, F.E.; Doll, R.; Heaf, P. Observations on recent increase in mortality from asthma. *Br. Med. J.* **1968**, *1*, 335–339.
145. Fraser, P.; Doll, R. Geographical variations in the epidemic of asthma deaths. *Br. J. Prev. Soc. Med.* **1971**, *25*, 34–36.
146. Jackson, R.T.; Beaglehole, R.; Rea, H.H.; Sutherland, D.C. Mortality from asthma : a new epidemic in New Zealand. *Br. Med. J.* **1982**, *285*, 771–774.
147. Speizer, F.E.; Doll, R.; Heaf, P.; Strang, L.B. Investigation into use of drugs preceding death from asthma. *Br. Med. J.* **1968**, *1*, 339–343.
148. Conolly, M.E.; Davies, D.S.; Dollery, C.T.; George, C.F. Resistance to beta-adrenoceptor stimulants (a possible explanation for the rise in ashtma deaths). *Br. J. Pharmacol.* **1971**, *43*, 389–402.
149. Wilson, J.D.; Sutherland, D.C.; Thomas, A.C. Has the change to beta-agonists combined with oral theophylline increased cases of fatal asthma? *Lancet* **1981**, *1*, 1235–1237.
150. Grant, I.W.B. Asthma in New Zealand. *Br. Med. J.* **1983**, *286*, 374–377.
151. Crane, J.; Flatt, A.; Jackson, R.; Ball, M.; Pearce, N.; Burgess, C.; Kwong, T.; Beasley, R. Prescribed fenoterol and death from asthma in New Zealand, 1981–83; Case-control study. *Lancet* **1989**, *1*, 917–922.
152. Pearce, N.; Grainger, J.; Atkinson, M.; Crane, J.; Burgess, C.; Culling, C.; Windom, H.; Beasley, R. Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977–81. *Thorax* **1990**, *45*, 170–175.
153. Spitzer, W.O.; Suissa, S.; Ernst, P.; Horwitz, R.I.; Habbick, B.; Cockcroft, D.; Boivin, J.F.; McNutt, M.; Buist, A.S.; Rebusck, A.S. The use of beta-agonists and the risk of death and near death from asthma. *N. Engl. J. Med.* **1992**, *326*, 501–506.
154. Taylor, D.R.; Sears, M.R.; Herbison, G.P.; Flannery, E.M.; Print, C.G.; Lake, D.C. Yates, D.M.; Lucas, M.K.; Li, Q. Regular inhaled beta agonist in asthma: effect on exacerbations and lung function. *Thorax* **1993**, *48*, 134–138.
155. Dennis, S.M.; Sharp, S.J.; Vickers, M.R.; Frost, C.D.; Crompton, G.K.; Barnes, P.J.; Lee, T.H. Regular inhaled salbutamol and asthma control: the TRUST randomized trial. *Lancet* **2000**, *355*, 1675–1679.
156. British Thoracic Society, National Asthma Campaign, Royal College of Physicians of London, General Practitioner in Asthma Group. The British Guidelines on Asthma Management 1995 Review and Position Statement. *Thorax* **1997**, *52*, Suppl. 1, S1–S20.
157. Ullman, A.; Svedmyr, N. Salmeterol, a new long-acting inhaled beta<sub>2</sub>-adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients. *Thorax* **1988**, *43*, 674–678.

158. Faulds, D.; Hollingshead, L.M.; Goa, K.L. Formoterol. A review of its pharmacologic properties and therapeutic efficacy in reversible obstructive airways disease. *Drugs* **1991**, *42*, 115–137.
159. Grove, A.; Lipworth, B.J. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. *Lancet* **1995**, *346*, 201–206.
160. Newnham, D.M.; McDevitt, D.G.; Lipworth, B.J. Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma. *Am. J. Med.* **1994**, *97*, 29–37.
161. Yates, D.H.; Kharitonov, S.A.; Barnes, P.J. An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting  $\beta_2$ -agonist. *Am. J. Respir. Crit. Care Med.* **1996**, *154*, 1603–1607.
162. Arvidsson, P.; Larsson, S.; Löfdahl, C-G.; Melander, B.; Svedmyr, N.; Wåhlander, L. Inhaled formoterol during one year in asthma: a comparison with salbutamol. *Eur. Respir. J.* **1991**, *4*, 1168-1173.
163. Castle, W.; Fuller, R.; Hall, J.; Palmer, J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. *Br. Med. J.* **1993**, *306*, 1034–1037.
164. Nelson, H.S.; Weiss, S.T.; Bleecker, E.R.; Yancey, S.W.; Dorinsky, P.M. The Salmeterol Multicenter Asthma Research Trial. A comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. *Chest* **2006**, *129*, 15–26.
165. Anderson, H.R.; Ayres, J.G.; Sturdy, P.M.; Bland, J.M.; Butland, B.K.; Peckitt, C.; Taylor, J.C.; Victor, C.R. Bronchodilator treatment and deaths from asthma: case-control study. *Br. Med. J.* **2005**, *330*, 117–123.
166. Maringe, C.; Rickard, K.; DiSantostefano, R.; Davis, K.; Kiri, V. Concomitant use of long-acting  $\beta$ -agonists with inhaled corticosteroids among asthma patients in the UK primary care. *Eur. Respir. J.* **2007**, *30*, Suppl. 51, P3698.
167. Food and Drug Administration Center for Drug Evaluation and Research. Summary Minutes of the Pulmonary-Allergy Drugs Advisory Committee. [www.fda.gov/ohrms/dockets/ac/05/minutes/2005-4148M1\\_Final.pdf/](http://www.fda.gov/ohrms/dockets/ac/05/minutes/2005-4148M1_Final.pdf/). Last accessed: July 2008. Last updated: June 13, 2005.
168. Mann, M.; Chowdhury, B.; Sullivan, E.; Nicklas, R.; Anthracite, R.; Meyer, R.J. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. *Chest* **2003**, *124*, 70–74.
169. Wolfe, J.; LaForce, C.; Friedman, B.; Sokol, W.; Till, D.; Della Cioppa, G.; van As, A. Formoterol, 24  $\mu$ g bid, and serious asthma exacerbations: similar rates compared with formoterol, 12  $\mu$ g bid, with and without extra doses taken on demand, and placebo. *Chest* **2006**, *129*, 27–38.
170. Sears, M.R.; Ottosson, A.; Radner, F.; Suissa, S. Long-acting  $\beta$ -agonists: a review of formoterol safety data from asthma clinical trials. *Eur. Respir. J.* **2009**, *33*, 21–32.
171. Battram, C.; Charlton, S.J.; Cuenoud, B.; Dowling, M.R.; Fairhurst, R.A.; Farr, D.; Fozard, J.R.; Leighton-Davies, J.R.; Lewis, C.A.; McEvoy, L.; *et al.* *In vitro* and *in vivo* pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1*H*-quinolin-2-one (indacaterol), a novel inhaled  $\beta_2$  adrenoceptor agonist with a 24-h duration of action. *J. Pharmacol. Exp. Ther.* **2006**, *317*, 762–770.

172. Sturton, R.G.; Trifilieff, A.; Nicholson, A.G.; Barnes, P.J. Pharmacological characterization of indacaterol, a novel once daily inhaled  $\beta_2$ -adrenoceptor agonist, on small airways in human and rat precision-cut lung slices. *J. Pharmacol. Exp. Ther.* **2008**, *324*, 270–275.
173. Beeh, K.M.; Derom, E.; Kanniess, F.; Cameron, R.; Higgins, M.; van As, A. Indacaterol, a novel inhaled  $\beta_2$ -agonist, provides sustained 24 h bronchodilation in asthma. *Eur. Respir. J.* **2007**, *29*, 871–878.
174. Pauwels, R.A.; Löfdahl, C.G.; Postma, D.S.; Tattersfield, A.E.; O’Byrne, P.; Barnes, P.J.; Ullman, A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. *N. Engl. J. Med.* **1997**, *337*, 1405–1411.
175. Price, D.; Dutchman, D.; Mawson, A.; Bodalia, B.; Duggan, S.; Todd, P. Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose. *Thorax* **2002**, *57*, 791–798.
176. Currie, G.P.; Lee, D.K.; Srivastava, P. Long-acting bronchodilator or leukotriene modifier as add-on therapy to inhaled corticosteroids in persistent asthma? *Chest* **2005**, *128*, 2954–2962.
177. FDA Public Health Advisory. Serevent Diskus (salmeterol xinafoate inhalation powder), Advair Diskus (fluticasone propionate & salmeterol inhalation powder), Foradil Aerolizer (formoterol fumarate inhalation powder). [www.fda.gov/cder/drug/advisory/LABA.htm](http://www.fda.gov/cder/drug/advisory/LABA.htm) Date last updated: May 15, 2006. Date last accessed: October 30, 2008.

© 2010 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/3.0/>).